Entering text into the input field will update the search result below

TCR² Therapeutics stock rise 41% after merger deal with Adaptimmune

Success business chart with green arrow up and USA dollars background. Profit and money. Financial and business graph. Stock market growth 3d illustration.


  • Adaptimmune Therapeutics (NASDAQ:ADAP) and TCR² Therapeutics (NASDAQ:TCRR) have entered into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors.
  • Shares of

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.